Business
Curaleaf International Launches Range of Medical Cannabis Products in Germany
Curaleaf International Launches Range of Medical Cannabis Products in Germany C...
About this update from Curaleaf Holdings, Inc.
[{"type":"text","content":"\n \n \n \n Curaleaf International Launches Range of Medical Cannabis Products in Germany\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Poised for Rapid Growth in\n \n Europe's\n \n Largest Medical Cannabis Market\n \n \n \n \n WAKEFIELD, Mass.\n \n ,\n \n May 11, 2021\n \n /CNW/ --\n \n Curaleaf Holdings, Inc.\n \n (CSE: CURA / OTCQX: CURLF)\n \n (\"Curaleaf\" or the \"Company\")\n \n , a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH (\"Adven\") has launched its own range of medical cannabis products in\n \n Germany\n \n ,\n \n Europe's\n \n largest medical cannabis market.  The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THC/CBD formulations in both oil and flower formats, addressing a wide range of patient needs.\n \n Germany\n \n is\n \n Europe's\n \n largest medical cannabis market and is expected to be worth\n \n US$2.1 billion\n \n by 2025\n \n 1\n \n .\n \n \n \n Antonio Costanzo\n \n , CEO of Curaleaf International, said, \"We are very pleased to bring our first medical cannabis products to market in\n \n Germany\n \n and, with the rapid extension of our product range in 2021, establishing ourselves as a leader in\n \n Europe's\n \n largest medical cannabis market. Curaleaf International's European supply chain, from cultivation to product research and development and EU-GMP manufacturing processes across\n \n Europe\n \n , means we are able to guarantee a consistency of product and price to clinicians and patients in need of the highest quality medical cannabis.\"\n \n \n Julian Vaterrodt, Managing Director, Adven GmbH, added,\n \n \n \"German patients and practitioners are increasingly demanding high-quality, consistent and reliable European natural alternatives to help manage a wide range of complaints.  Adven is committed to providing a differentiated product and service fo...